Literature DB >> 23305218

Impact of reproductive status and age on response of depressed women to cognitive therapy.

Anna R Brandon1, Abu Minhajuddin, Michael E Thase, Robin B Jarrett.   

Abstract

OBJECTIVE: Previous research suggests that reproductive hormones are potential affective modulators in mood disorders and may influence response to antidepressant medications. To our knowledge, there are no data on relationships between hormonal status and response to psychotherapy for recurrent major depressive disorder (MDD).
METHODS: At two sites, female outpatients (n=353), aged 18-70, with recurrent MDD received 12-14 weeks of cognitive therapy (CT). Menopausal status and age were based on self-report. In the parent study, nonresponse to therapy was defined as persistence of a major depressive episode (MDE) as defined by the DSM-IV or a final Hamilton Rating Scale for Depression-17-Item (HRSD(17)) score of ≥ 12 or both. More traditional definitions of response (at least a 50% reduction in pretreatment HRSD(17)) and remission (a final HRSD(17) ≤ 6) were also examined.
RESULTS: Controlling for pretreatment HRSD(17) scores, there were no significant differences found in the rates of response to CT or symptom status among premenopausal, perimenopausal, and postmenopausal women.
CONCLUSIONS: We found no support for the hypotheses that response to CT or the rates of change in depressive symptoms are moderated by reproductive status. The findings, however, are limited by the absence of early follicular phase serum sampling/analysis to estimate hormone levels and the reliance on self-report to establish menopausal status. These data motivate a full investigation of the effects of reproductive status on response to psychosocial interventions.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23305218      PMCID: PMC3546363          DOI: 10.1089/jwh.2011.3427

Source DB:  PubMed          Journal:  J Womens Health (Larchmt)        ISSN: 1540-9996            Impact factor:   2.681


  37 in total

Review 1.  Gender-specific response to depression treatment.

Authors:  E Frank; M E Thase; C A Spanier; C F Reynolds; D J Kupfer
Journal:  J Gend Specif Med       Date:  1999 Jul-Aug

2.  Are there differences between women's and men's antidepressant responses?

Authors:  Frederic M Quitkin; Jonathan W Stewart; Patrick J McGrath; Bonnie P Taylor; Mayra S Tisminetzky; Eva Petkova; Ying Chen; Guoguang Ma; Donald F Klein
Journal:  Am J Psychiatry       Date:  2002-11       Impact factor: 18.112

3.  Reliability of DSM-IV anxiety and mood disorders: implications for the classification of emotional disorders.

Authors:  T A Brown; P A Di Nardo; C L Lehman; L A Campbell
Journal:  J Abnorm Psychol       Date:  2001-02

4.  A comparison of two rating scales for depression.

Authors:  J J Schwab; M R Bialow; C E Holzer
Journal:  J Clin Psychol       Date:  1967-01

Review 5.  Epidemiology of depression throughout the female life cycle.

Authors:  Vivien K Burt; Kira Stein
Journal:  J Clin Psychiatry       Date:  2002       Impact factor: 4.384

6.  Gender differences in treatment response to sertraline versus imipramine in chronic depression.

Authors:  S G Kornstein; A F Schatzberg; M E Thase; K A Yonkers; J P McCullough; G I Keitner; A J Gelenberg; S M Davis; W M Harrison; M B Keller
Journal:  Am J Psychiatry       Date:  2000-09       Impact factor: 18.112

7.  Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo.

Authors:  A R Entsuah; H Huang; M E Thase
Journal:  J Clin Psychiatry       Date:  2001-11       Impact factor: 4.384

8.  Epidemiology of women and depression.

Authors:  Ronald C Kessler
Journal:  J Affect Disord       Date:  2003-03       Impact factor: 4.839

9.  Gender differences in treatment response to sertraline versus imipramine in patients with nonmelancholic depressive disorders.

Authors:  Enrique Baca; Margarida Garcia-Garcia; Alberto Porras-Chavarino
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2004-01       Impact factor: 5.067

10.  Persistent mood symptoms in a multiethnic community cohort of pre- and perimenopausal women.

Authors:  Joyce T Bromberger; Susan F Assmann; Nancy E Avis; Miriam Schocken; Howard M Kravitz; Adriana Cordal
Journal:  Am J Epidemiol       Date:  2003-08-15       Impact factor: 4.897

View more
  3 in total

Review 1.  Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 6. Special Populations: Youth, Women, and the Elderly.

Authors:  Glenda M MacQueen; Benicio N Frey; Zahinoor Ismail; Natalia Jaworska; Meir Steiner; Ryan J Van Lieshout; Sidney H Kennedy; Raymond W Lam; Roumen V Milev; Sagar V Parikh; Arun V Ravindran
Journal:  Can J Psychiatry       Date:  2016-08-02       Impact factor: 4.356

Review 2.  Nonpharmacologic treatments for depression related to reproductive events.

Authors:  Anna R Brandon; Shannon K Crowley; Jennifer L Gordon; Susan S Girdler
Journal:  Curr Psychiatry Rep       Date:  2014-12       Impact factor: 5.285

3.  Development and validation of a new rating scale for perimenopausal depression-the Meno-D.

Authors:  Jayashri Kulkarni; Emorfia Gavrilidis; Abdul-Rahman Hudaib; Caitlin Bleeker; Roisin Worsley; Caroline Gurvich
Journal:  Transl Psychiatry       Date:  2018-06-28       Impact factor: 6.222

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.